Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9899)
All Articles published online
|
Publishing Process of This Article
|
Sep 21, 2016 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i35/8050.htm |
| Number | Citing Articles |
| 1 |
Christina Sølund, Sofie Hallager, Martin S. Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B. Krarup, Birgit T. Røge, Peer B. Christensen, Alex L. Laursen, Jan Gerstoft, Erika Bélard, Lone G. Madsen, Kristian Schønning, Anders G. Pedersen, Jens Bukh, Nina Weis. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scandinavian Journal of Gastroenterology 2018; 53(7): 849 doi: 10.1080/00365521.2018.1467963
|
| 2 |
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.550205
|
| 3 |
M G Artemova, D T Abdurakhmanov. Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects. Terapevticheskii arkhiv 2017; 89(4): 110 doi: 10.17116/terarkh2017894110-114
|
| 4 |
Paula Eckardt, Jianli Niu, Angela Savage, Tara Griffin, Elizabeth Sherman. Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital. Journal of the International Association of Providers of AIDS Care (JIAPAC) 2019; 18 doi: 10.1177/2325958219835590
|
| 5 |
Thalia Medeiros, Camila de Morais Salviato, Natalia Fonseca do Rosário, Geórgia do Nascimento Saraiva, Eliane Bordalo Cathalá Esberard, Jorge Reis Almeida, Analúcia Rampazzo Xavier, Andrea Alice da Silva. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. International Journal of Clinical Pharmacy 2017; 39(6): 1304 doi: 10.1007/s11096-017-0552-1
|
| 6 |
|
| 7 |
Frank A. Fanizza, Jennifer Loucks, Angelica Berni, Meera Shah, Dennis Grauer, Sarah Daniel. Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology Clinic. Hospital Pharmacy 2022; 57(3): 370 doi: 10.1177/00185787211037540
|
| 8 |
Vijay Gayam, Muhammad Rajib Hossain, Mazin Khalid, Sandipan Chakaraborty, Osama Mukhtar, Sumit Dahal, Amrendra Kumar Mandal, Arshpal Gill, Pavani Garlapati, Sreedevi Ramakrishnaiah, Khalid Mowyad, Jagannath Sherigar, Mohammed Mansour, Smruti Mohanty. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. Gut and Liver 2018; 12(6): 694 doi: 10.5009/gnl18004
|
| 9 |
Tchadine Djaogol, Hélène Fontaine, Maël Baudoin, Camelia Protopopescu, Fabienne Marcellin, Céline Dorival, Mélanie Simony, Ventzislava Petrov‐Sanchez, Marc Bourlière, Elisabeth Delarocque‐Astagneau, Stanislas Pol, Fabrice Carrat, Patrizia Carrieri. Effectiveness of direct‐acting antivirals for chronic hepatitis C treatment in migrant and non‐migrant populations in France. Liver International 2021; 41(10): 2328 doi: 10.1111/liv.14823
|
| 10 |
Lone Wulff Madsen, Peer Brehm Christensen, Anne Øvrehus, Dorthe Marie Sjødahl Bryde, Dorte Kinggaard Holm, Søren Thue Lillevang, Christian Nielsen. Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.885824
|
| 11 |
Lijoy Varghese, Sharifa Ezat Wan Puteh, Nadia Schecroun, Rohani Jahis, Ilse Van Vlaenderen, Baudouin A. Standaert. Applying a Constrained Optimization Portfolio Model to Aid Prioritization of Public Health Interventions in Malaysia. Value in Health Regional Issues 2020; 21: 172 doi: 10.1016/j.vhri.2019.11.001
|
| 12 |
Vered Richter, Liav Goldstein, Daniel L Cohen, Anton Bermont, Dana Zelnik Yovel, Miriam Madar, Ron Rabinovitch, Haim Shirin, Efrat Broide. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons. Science Progress 2022; 105(2) doi: 10.1177/00368504221105173
|
| 13 |
Jianhong Chen, Xiaxia Zhang, Hao Luo, Chihong Wu, Min Yu, Dan Liu, Hongli Xi, Yihang Zhou, Yaoyu An, Xiaoyuan Xu. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. Oncotarget 2017; 8(53): 90916 doi: 10.18632/oncotarget.18701
|
| 14 |
Giuseppe Bruno, Annalisa Saracino, Luigia Scudeller, Claudia Fabrizio, Raffaele Dell’Acqua, Eugenio Milano, Michele Milella, Nicoletta Ladisa, Laura Monno, Gioacchino Angarano. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?. International Journal of Infectious Diseases 2017; 62: 64 doi: 10.1016/j.ijid.2017.07.001
|
| 15 |
Mohammad Saeid Rezaee-Zavareh, Khashayar Hesamizadeh, Heidar Sharafi, Seyed Moayed Alavian. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. Hepatitis Monthly 2017; 17(6) doi: 10.5812/hepatmon.12324
|
| 16 |
Kimberly E. Daniel, Kia Saeian, Syed Rizvi. Real‐world experiences with direct‐acting antiviral agents for chronic hepatitis C treatment. Journal of Viral Hepatitis 2020; 27(2): 195 doi: 10.1111/jvh.13218
|
| 17 |
Sheng Tang, Zong-Gen Peng, Ying-Hong Li, Xin Zhang, Tian-Yun Fan, Jian-Dong Jiang, Yan-Xiang Wang, Dan-Qing Song. Synthesis and biological evaluation of tricyclic matrinic derivatives as a class of novel anti-HCV agents. Chemistry Central Journal 2017; 11(1) doi: 10.1186/s13065-017-0327-8
|
| 18 |
Jeffrey W Jansen, Travis W Linneman, Gillian M Powderly, Ryan P Moenster, Leela Nayak. Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir. Open Forum Infectious Diseases 2019; 6(3) doi: 10.1093/ofid/ofz087
|
| 19 |
G Ireland, R Simmons, M Hickman, M Ramsay, C Sabin, S Mandal. Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017.
Eurosurveillance 2019; 24(41) doi: 10.2807/1560-7917.ES.2019.24.41.1900176
|
| 20 |
Sreekumar Othumpangat, Sidhartha D. Ray, John D. Noti. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2017; 39: 269 doi: 10.1016/bs.seda.2017.07.002
|
| 21 |
Julia L. Casey, Jordan J. Feld, Sonya A. MacParland. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. Cells 2019; 8(4): 317 doi: 10.3390/cells8040317
|
| 22 |
Daniele Lapa, Paola Del Porto, Claudia Minosse, Gianpiero D’Offizi, Andrea Antinori, Maria Rosaria Capobianchi, Ubaldo Visco-Comandini, Fiona McPhee, Anna Rosa Garbuglia, Mauro Zaccarelli. Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy. Journal of Clinical Medicine 2021; 10(10): 2092 doi: 10.3390/jcm10102092
|
| 23 |
Muhammad H. Bashir, Javid Fazili, Mohammad F. Madhoun, Rajesh Kanagala, Sixia Chen, Salman Nusrat. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. European Journal of Gastroenterology & Hepatology 2018; 30(3): 296 doi: 10.1097/MEG.0000000000001032
|
| 24 |
Marwa K. Ibrahim, Mohamed AbdElrahman, Noha G. Bader El Din, Salwa Tawfik, Sherief Abd-Elsalam, Dalia Omran, Amal Z. Barakat, Sally Farouk, Hassan Elbatae, Mostafa K. El Awady. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial Pathogenesis 2022; 162: 105311 doi: 10.1016/j.micpath.2021.105311
|
| 25 |
Julia M. Grottenthaler, Christoph R. Werner, Martina Steurer, Ulrich Spengler, Thomas Berg, Cornelius Engelmann, Heiner Wedemeyer, Thomas von Hahn, Wolfgang Stremmel, Anita Pathil, Ulrich Seybold, Eckart Schott, Usha Blessin, Christoph Sarrazin, Martin-Walter Welker, Ellen Harrer, Stefan Scholten, Clemens Hinterleitner, Ulrich M. Lauer, Nisar P. Malek, Christoph P. Berg, Chen-Hua Liu. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLOS ONE 2018; 13(6): e0197544 doi: 10.1371/journal.pone.0197544
|
| 26 |
Jeffrey W. Jansen, Gillian M. Powderly, Travis W. Linneman. Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir. Annals of Pharmacotherapy 2017; 51(7): 543 doi: 10.1177/1060028017693348
|
| 27 |
Timothy Papaluca, Marie Sinclair, Paul Gow, Stephen Pianko, William Sievert, Niranjan Arachchi, Karla Cameron, Scott Bowden, Jacinta O’Keefe, Joseph Doyle, Mark Stoove, Margaret Hellard, David Iser, Alexander Thompson. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. Liver International 2019; 39(12): 2285 doi: 10.1111/liv.14201
|
| 28 |
Stefania Paolucci, Marta Premoli, Stefano Novati, Roberto Gulminetti, Renato Maserati, Giorgio Barbarini, Paolo Sacchi, Antonio Piralla, Davide Sassera, Leone De Marco, Alessia Girello, Mario U. Mondelli, Fausto Baldanti. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-15987-1
|
| 29 |
Elena Perpiñán, Noelia Caro‐Pérez, Neris García‐González, Josep Gregori, Patricia González, Concepción Bartres, Maria Eugenia Soria, Celia Perales, Sabela Lens, Zoe Mariño, María Carlota Londoño, Xavier Ariza, George Koutsoudakis, Josep Quer, Fernando González‐Candelas, Xavier Forns, Sofía Pérez‐del‐Pulgar. Hepatitis C virus early kinetics and resistance‐associated substitution dynamics during antiviral therapy with direct‐acting antivirals. Journal of Viral Hepatitis 2018; 25(12): 1515 doi: 10.1111/jvh.12986
|
| 30 |
Timothy Papaluca, Stuart K Roberts, Simone I Strasser, Katherine A Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J Dore, Amanda J Wade, Jacob George, Simon Hazeldine, James O’Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson, Aidan Woodward, Golo Ahlenstiel, Mazhar Haque, Miriam Levy, Emily Prewett, William Sievert, Siddharth Sood, Edmund Tse, Zina Valaydon, Scott Bowden, Mark Douglas, Kate New, Jacinta O’Keefe, Margaret Hellard, Joseph Doyle, Mark Stoove, Alexander J Thompson. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clinical Infectious Diseases 2021; 73(9): e3288 doi: 10.1093/cid/ciaa1318
|
| 31 |
Ahmed KAMAL, Cecil MATTA, Heba Akram MOHSIN, Abeer Shawki ELHADIDI, Ramy Mohamed GHAZY, Heba Hany OMAR, Mona TAHOUN, Nema Abdelhameed MOHAMED. ASSESSING PREDICTORS OF DIRECTLY ACTING ANTIVIRALS’ FAILURE AS A FURTHER STEP TOWARDS MORE EFFICIENT HCV ELIMINATION PROGRAMS: IL28B (IFNL4) GENE POLYMORPHISM HAS NO ROLE WHILE HIGHER ESTIMATED CREATININE CLEARANCE IS A FORGOTTEN FACTOR. Arquivos de Gastroenterologia 2022; 59(2): 177 doi: 10.1590/s0004-2803.202202000-33
|
| 32 |
Necla Kulabaş, Jin-Ching Lee, Özlem Bingöl Özakpınar, İlkay Küçükgüzel. Synthesis and anti-HCV activity of novel 5-arylmethylene-1,3-thiazolidin-4-one derivatives via suppression of NS5B polymerase and COX-2. Journal of Molecular Structure 2024; 1311: 138407 doi: 10.1016/j.molstruc.2024.138407
|
| 33 |
T. Semenova, B. Nemoz, V. Thibault, G. Lagathu, G. Duverlie, E. Brochot, P. Trimoulet, C. Payan, S. Vallet, C. Henquell, S. Chevaliez, M. Bouvier-Alias, S. Maylin, A-M. Roque-Afonso, L. Izquierdo, F. Lunel-Fabiani, P. Marcellin, P. Morand, V. Leroy, S. Larrat. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study. Epidemiology and Infection 2019; 147 doi: 10.1017/S0950268819001225
|
| 34 |
Badreddin Shaibani, Khairi Ayad, Marwa Melodi, Sabah Albarasi, Badereddin Annajar, Mahdi Jibani. Outcome of Treatment for Hepatitis C Infection in Hemodialysis Patients with Direct-Acting Second-Generation anti-HCV Drugs at Azzawiyah Kidney Hospital, Libya. Libyan Journal of Medical Sciences 2022; 6(2): 53 doi: 10.4103/ljms.ljms_39_21
|
| 35 |
Jian-Hong Chen, Zheng Zeng, Xia-Xia Zhang, Yu Zhang, Ren-Wen Zhang, Shuai Wang, Chi-Hong Wu, Min Yu, Dan Liu, Hong-Li Xi, Yi-Xing Zhou, Yao-Yu An, Xiao-Yuan Xu. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting. World Journal of Gastroenterology 2017; 23(22): 4072-4079 doi: 10.3748/wjg.v23.i22.4072
|
| 36 |
Linda Henry, Zobair Younossi. Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 2016; 16(6): 659 doi: 10.1080/14737167.2016.1244007
|
| 37 |
Bruna Forte Aguiar, Guilherme Rodrigues Fernandes Campos, João Paulo Vilela Rodrigues, Nayara Nathie Marques, Bárbara Floriano Molina, Cintia Bittar, Fernanda Fernandes Souza, Ana de Lourdes Candolo Martinelli, Paula Rahal, Leonardo Régis Leira Pereira. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil. Clinics and Research in Hepatology and Gastroenterology 2020; 44(3): 329 doi: 10.1016/j.clinre.2019.07.015
|
| 38 |
Tian Zeng, Peng Huang, Weilong Tan, Zepei Feng, Jianguo Shao, Xueshan Xia, Chao Shen, Liqin Qian, Bingqing Wang, Zhengjie Li, Chuanlong Zhu, Yun Zhang, Ming Yue. Efficacy and safety of directly acting antiviral drugs in HCV patients with HIV in liver transplantation: A meta-analysis. Decoding Infection and Transmission 2023; 1: 100005 doi: 10.1016/j.dcit.2023.100005
|
| 39 |
Manar Ahmed, Azza E. Mansey, Engy A. Wahsh, Ahmed A. Gomaa, Hoda M. Rabea. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. Current Medical Science 2021; 41(3): 581 doi: 10.1007/s11596-021-2363-9
|